CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis
Hui Zheng, Jingsong Cheng, Jialin Liu, Guodong Liu, Ronglun Dang, Rugang Luo, Jinhe Lou, Pengpeng Zhang · 2025
Read CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis by Hui Zheng, Jingsong Cheng, Jialin Liu, Guodong Liu, Ronglun Dang, Rugang Luo, Jinhe Lou, Pengpeng Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717531.txt.
Description
Hui Zheng and co-authors wrote a 2025 paper on a gene that may predict how brain tumors behave. Gliomas are cancers of the brain's support tissue, and their course varies widely. The claudin family of genes helps seal cell sheets, and its role in gliomas was unclear. The team focused on one member, CLDN22.
They mined a large public cancer atlas with many kinds of molecular data. Tumors were grouped into subtypes, and machine learning tools picked out the features that matter most. Immune profiling checked how the gene relates to the cells around the tumor. The authors argue this gene marks both outlook and likely response to immune therapy. Such markers could help doctors sort patients for trials.
Catalog record
| CREATOR | Hui Zheng, Jingsong Cheng, Jialin Liu, Guodong Liu, Ronglun Dang, Rugang Luo, Jinhe Lou, Pengpeng Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |